5 结果
The invention relates to the use of polyunsaturated fatty acids for the primary prevention of major cardiovascular events.
In particular, the invention concerns the use of polyunsaturated fatty acids of the .omega.-3 series such as eicosapentaenoic acid (EPA, C.sub.20:5 .omega.-3) docosahexaenoic
The invention relates to the use of polyunsaturated fatty acids for the primary prevention of major cardiovascular events.
In particular, the invention concerns the use of polyunsaturated fatty acids of the .omega.-3 series such as eicosapentaenoic acid (EPA, C.sub.20:5 .omega.-3), docosahexaenoic
The invention relates to the use of polyunsaturated fatty acids for the primary prevention of major cardiovascular events.
In particular, the invention concerns the use of polyunsaturated fatty acids of the .omega.-3 series such as eicosapentaenoic acid (EPA, C.sub.20:5 .omega.-3), docosahexaenoic
CROSS-REFERENCE TO RELATED APPLICATIONS
This is the U.S. National Stage of PCT/EP00/00957, filed Feb. 7, 2000, which claims priority to Italian patent application no. MI99A000313, filed Feb. 17, 1999, both of which are incorporated herein in their entirety by reference.
This invention concerns the
BACKGROUND OF THE INVENTION
The invention relates to the prevention of ventricular fibrillation. Ventricular fibrillation can lead to sudden death, and occurs primarily in patients having myocardial infarction or other conditions which cause ischemia of cardiac tissue. The high incidence of